{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:15:24Z","timestamp":1775542524973,"version":"3.50.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82530056"],"award-info":[{"award-number":["82530056"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271749"],"award-info":[{"award-number":["82271749"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201905"],"award-info":[{"award-number":["82201905"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2701704"],"award-info":[{"award-number":["2021YFC2701704"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2701700"],"award-info":[{"award-number":["2021YFC2701700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thromboembolic events (TE) are increasingly recognized in pediatric patients, necessitating optimal antithrombotic therapy. While direct oral anticoagulants (DOACs) offer potential advantages over standard of care (SOC) such as heparin, comprehensive evidence regarding their use for treatment and prophylaxis remains limited. Therefore, we performed a systematic review and meta-analysis to assess the efficacy and safety of these two classes of anticoagulants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We searched PubMed, Embase, Web of Science, and\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      up to November 27, 2025, for relevant randomized controlled trials (RCTs) comparing DOACs with SOC in pediatric patients. Data were synthesized using fixed- or random-effects models to calculate risk ratios (RRs) with 95% confidence intervals (CIs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eight RCTs involving 2,002 pediatric patients were included. In terms of efficacy, DOACs were associated with a significant reduction in TE recurrence in treatment studies (\n                      <jats:italic>RR<\/jats:italic>\n                      = 0.50; 95% CI 0.25\u20130.99) and TE occurrence in prophylaxis studies (\n                      <jats:italic>RR<\/jats:italic>\n                      = 0.63; 95% CI 0.42\u20130.95). Regarding safety, major bleeding was comparable to SOC with a favorable trend observed for DOACs (\n                      <jats:italic>RR<\/jats:italic>\n                      = 0.64; 95% CI 0.26\u20131.55). No significant differences were found in all-cause mortality and serious adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DOACs represent an effective alternative to SOC for the treatment and prevention of thromboembolism in children, demonstrating superior efficacy without increasing the risk of bleeding events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      PROSPERO\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024506541<\/jats:ext-link>\n                      , CRD42024506541.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1787819","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:34:51Z","timestamp":1775540091000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of direct oral anticoagulants in pediatric patients: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Siyi","family":"You","sequence":"first","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Ultrasonography, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, NHC Key Laboratory of Chronobiology, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dezhi","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, NHC Key Laboratory of Chronobiology, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1182\/asheducation-2018.1.399","article-title":"Management of thrombosis in children and neonates: practical use of anticoagulants in children","volume":"2018","author":"Monagle","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.thromres.2020.01.017","article-title":"Central venous catheter-related thrombosis in children and adults","volume":"187","author":"Citla Sridhar","year":"2020","journal-title":"Thromb Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e2021054649","DOI":"10.1542\/peds.2021-054649","article-title":"The continued rise of venous thromboembolism across US Children's Hospitals","volume":"149","author":"O'Brien","year":"2022","journal-title":"Pediatrics."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1542\/peds.2009-0768","article-title":"Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007","volume":"124","author":"Raffini","year":"2009","journal-title":"Pediatrics."},{"key":"B5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1182\/blood.2022018966","article-title":"How I treat pediatric venous thromboembolism in the DOAC era","volume":"143","author":"Bhat","year":"2024","journal-title":"Blood."},{"key":"B6","doi-asserted-by":"publisher","first-page":"Cd006468","DOI":"10.1002\/14651858.CD006468.pub6","article-title":"Anticoagulation for people with cancer and central venous catheters","volume":"6","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jtcvs.2019.07.011","article-title":"Commentary: thromboprophylaxis after congenital cardiac surgery-Time for evidence-based guidelines","volume":"158","author":"Scott","year":"2019","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/S2352-3026(23)00339-3","article-title":"Thromboprophylaxis in paediatric acute lymphoblastic leukaemia","volume":"11","author":"Athale","year":"2024","journal-title":"Lancet Haematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1182\/bloodadvances.2018024786","article-title":"American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism","volume":"2","author":"Monagle","year":"2018","journal-title":"Blood Adv."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2308","article-title":"Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","author":"Monagle","year":"2012","journal-title":"Chest."},{"key":"B11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S2352-4642(21)00343-6","article-title":"Direct oral anticoagulants for use in paediatrics","volume":"6","author":"Jaffray","year":"2022","journal-title":"Lancet Child Adolesc Health."},{"key":"B12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin Pharmacol Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.hrthm.2024.11.041","article-title":"Managing drug-drug interactions with mavacamten: a focus on combined use of antiarrhythmic drugs and anticoagulants","volume":"22","author":"Ricci","year":"2025","journal-title":"Heart Rhythm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1016\/j.jtha.2024.08.006","article-title":"The use of direct oral anticoagulants in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC subcommittee on physiological anticoagulants and thrombophilia","volume":"22","author":"Kovac","year":"2024","journal-title":"J Thromb Haemost."},{"key":"B15","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1055\/s-0043-1778106","article-title":"Venous Thromboembolism in Children: The Rivaroxaban Experience","volume":"50","author":"Spiezia","year":"2024","journal-title":"Semin Thromb Hemost."},{"key":"B16","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1161\/CIRCULATIONAHA.123.064556","article-title":"Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants","volume":"148","author":"Aggarwal","year":"2023","journal-title":"Circulation."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs. low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"Jama."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.2139\/ssrn.3624247","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost."},{"key":"B21","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj."},{"key":"B22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics."},{"key":"B23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.34172\/PS.2020.42","article-title":"Dabigatran versus warfarin for the treatment of pediatric thromboembolism: a pilot randomized trial","volume":"26","author":"Eghbali","year":"2020"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e020766","DOI":"10.1161\/JAHA.120.020766","article-title":"Thromboprophylaxis for children post-Fontan procedure: insights from the universe study","volume":"10","author":"McCrindle","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.jacc.2022.09.031","article-title":"Edoxaban for thromboembolism prevention in pediatric patients with cardiac disease","volume":"80","author":"Portman","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.jacc.2023.10.010","article-title":"Apixaban for prevention of thromboembolism in pediatric heart disease","volume":"82","author":"Payne","year":"2023","journal-title":"J Am Coll Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/S2352-3026(23)00314-9","article-title":"Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial","volume":"11","author":"O'Brien","year":"2024","journal-title":"Lancet Haematol."},{"key":"B28","unstructured":"Apixaban for the Acute Treatment of Venous Thromboembolism in Children (NCT02464969)\n          \n          2024"},{"key":"B29","doi-asserted-by":"publisher","first-page":"13378","DOI":"10.1038\/s41598-024-64334-8","article-title":"Efficacy and safety of antithrombotic therapy for preventing and treating pediatric thromboembolic disease: a systematic review","volume":"14","author":"Gao","year":"2024","journal-title":"Sci Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e30076","DOI":"10.1002\/pbc.30076","article-title":"Barriers to medication adherence in children, adolescents, and young adults prescribed anticoagulation","volume":"70","author":"Todd","year":"2023","journal-title":"Pediatr Blood Cancer."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1111\/jth.15730","article-title":"Results of an international survey on adherence with anticoagulation in children, adolescents, and young adults: communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis","volume":"20","author":"McGrady","year":"2022","journal-title":"J Thromb Haemost."},{"key":"B32","doi-asserted-by":"publisher","first-page":"j5058","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"Bmj."},{"key":"B33","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1080\/13696998.2025.2514381","article-title":"Nationwide extrapolation of economic benefit of therapeutic innovation: a 10-year retrospective budget impact of direct oral anticoagulants introduction in France","volume":"28","author":"Guilmet","year":"2025","journal-title":"J Med Econ."},{"key":"B34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cpt.3689","article-title":"Characterization of apixaban pharmacokinetics\/pharmacodynamics and dose assessment in pediatric patients with congenital or acquired heart disease","volume":"118","author":"Ajavon-Hartmann","year":"2025","journal-title":"Clin Pharmacol Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1160\/TH15-04-0275","article-title":"Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents an open-label phase IIa study","volume":"116","author":"Halton","year":"2016","journal-title":"Thromb Haemost."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1016\/j.jtha.2023.07.011","article-title":"Efficacy and safety of direct oral anticoagulants in the pediatric population: a systematic review and a meta-analysis","volume":"21","author":"Giossi","year":"2023","journal-title":"J Thromb Haemost."},{"key":"B37","doi-asserted-by":"publisher","first-page":"10760296241271386","DOI":"10.1177\/10760296241271386","article-title":"Direct oral anticoagulants for treating acute venous thromboembolism in children: meta-analysis of randomized controlled trials","volume":"30","author":"Yu","year":"2024","journal-title":"Clin Appl Thromb Hemost."},{"key":"B38","doi-asserted-by":"publisher","first-page":"100001","DOI":"10.1016\/j.rpth.2022.100001","article-title":"Direct oral anticoagulants in pediatric venous thromboembolism: experience in specialized pediatric hemostasis centers in the United States","volume":"7","author":"Corrales-Medina","year":"2023","journal-title":"Res Pract Thromb Haemost."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3026(25)00067-5","article-title":"Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial","volume":"12","author":"Male","year":"2025","journal-title":"Lancet Haematol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1182\/blood.2019000998","article-title":"Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children","volume":"135","author":"Brand\u00e3o","year":"2020","journal-title":"Blood."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e42591","DOI":"10.1097\/MD.0000000000042591","article-title":"Causal effects of childhood obesity on venous thromboembolism in adulthood: a bidirectional Mendelian randomization study","volume":"104","author":"Zhou","year":"2025","journal-title":"Medicine."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1182\/bloodadvances.2025016160","article-title":"Safety and efficacy of apixaban thrombosis prevention in pediatric patients with obesity and acute lymphoblastic leukemia","volume":"9","author":"Rodriguez","year":"2025","journal-title":"Blood Adv."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e31140","DOI":"10.1002\/pbc.31140","article-title":"Direct oral anticoagulant use in hospitalized pediatric patients: Insights from nationwide data","volume":"71","author":"Buxton","year":"2024","journal-title":"Pediatr Blood Cancer."},{"key":"B44","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jacc.2023.10.038","article-title":"When direct oral anticoagulants should not be standard treatment: JACC state-of-the-art review","volume":"83","author":"Bejjani","year":"2024","journal-title":"J Am Coll Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jtha.2023.03.005","article-title":"Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease","volume":"21","author":"VanderPluym","year":"2023","journal-title":"J Thromb Haemost."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1111\/jth.14813","article-title":"Rivaroxaban for treatment of pediatric venous thromboembolism. an Einstein-Jr phase 3 dose-exposure-response evaluation","volume":"18","author":"Young","year":"2020","journal-title":"J Thromb Haemost."},{"key":"B47","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11239-016-1465-x","article-title":"Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)","volume":"43","author":"Hakeam","year":"2017","journal-title":"J Thromb Thrombolysis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e102312","DOI":"10.1016\/j.rpth.2023.102312","article-title":"Apixaban overdose in children: case report and proposed management. a brief communication from the pediatric and neonatal thrombosis and hemostasis SSC of ISTH","volume":"8","author":"Wiggins","year":"2024","journal-title":"Res Pract Thromb Haemost."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1182\/bloodadvances.2025016681","volume":"9","year":"2025","journal-title":"Blood Adv."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1787819\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:34:53Z","timestamp":1775540093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1787819\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":49,"alternative-id":["10.3389\/fpubh.2026.1787819"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1787819","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"article-number":"1787819"}}